Clinical Professor, Rheumatology, University of Washington School of Medicine
Rheumatology
Dr. Philip J. Mease, MD
|
|
Give Review
Philip Mease is an expert in the field of Rheumatology. He researched medicine at Stanford University School of Medicine. Stanford University School of Medicine is a one of the best medicals schools. Stanford University School of Medicine has a rank of 2 in research and a 25 in primary care He over the years received 3 awards: "America's Top Doctors", "Top MD" and "Super Doctor". Philip Mease is a published MD. He has 102 publications published. The most current publication "Ms. A.M. Taylor, et al reply." He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.
- Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthri...
- Biologic Therapy for Psoriatic Arthritis.
- Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musc...
- Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis.
- Patients with psoriatic Arthritis who achieve minimal disease activity in response to golimumab therapy demonstrate less radiographic progression: Results through 5 ye...
- Randomized Controlled Trial of Adalimumab in Patients with Non-Psoriatic Peripheral SpondyloArthritis.
- Effective management of psoriasis and psoriatic Arthritis: Insights on current and emerging therapies and enhanced professional collaboration.
- The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid Arthritis.
- Drug therapies for peripheral joint disease in psoriatic Arthritis: a systematic review.
- The Concept of Axial SpondyloArthritis: SPARTAN and ASAS joint Statement in response to FDA's comments and concerns.
- Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic Arthritis.
- Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of p...
- Comparative performance of psoriatic Arthritis screening tools in patients with psoriasis in European/North American dermatology clinics.
- Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting.
- A Comparison of the Malignancy Incidence Among Patients With Psoriatic Arthritis and Patients With Rheumatoid Arthritis in a Large US Cohort.
- GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral SpondyloArthritis Epidemiology Project.
- Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2013 GRAPPA Annual Meeting.
- The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting.
- Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to Pain and function: pooled analysis of 3 fibromyalgia trials.
- Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic Arthritis: results from a lon...
- Treatment of psoriatic Arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
- Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis.
- Long-Term Evaluation of Opioid Treatment in Fibromyalgia.
- Longitudinal Observation of Treatment Patterns and Outcomes for Patients with Fibromyalgia: 12-Month Findings from the REFLECTIONS Study.
- Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
- Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2012 Annual Mee...
- Peripheral SpondyloArthritis and Psoriatic Arthritis; Overlaps and Distinctions: A Report from the GRAPPA 2012 Annual Meeting.
- Psoriasis and Psoriatic Arthritis Video Project: An Update from the 2012 GRAPPA Annual Meeting.
- GRAPPA Educational Initiatives: A report from the GRAPPA 2012 Annual Meeting.
- Prevalence of rheumatologist-diagnosed psoriatic Arthritis in patients with psoriasis in European/North American dermatology clinics.
- Effect of certolizumab pegol on signs and symptoms in patients with psoriatic Arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study ...
- Milnacipran combined with pregabalin in Fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomple...
- Development and presentation of the first SPARTAN-GRAPPA educational symposium.
- Psoriatic Arthritis and spondyloArthritis assessment and management update.
- Improvements in productivity at paid work and within household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patie...
- Patient reported outcomes and the association with clinical response in patients with active psoriatic Arthritis treated with golimumab: Findings through 2 years of th...
- Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters.
- Updated consensus statement on biological agents for the treatment of rheumatic Diseases, 2012.
- Documentation of off-label use of biologics in Rheumatoid Arthritis.
- Safety of Rituximab in Combination with Other Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: An Open-label Study.
- Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT.
- Reduced joint counts misclassify psoriatic Arthritis patients with oligoArthritis and miss significant active disease.
- Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic Arthritis patients treated with golimumab.
- Update on treatment of psoriatic Arthritis.
- Is there a role for rituximab in the treatment of spondyloArthritis and psoriatic Arthritis?
- Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic Arthritis: results from a long-term extens...
- Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
- Biomarkers of Radiographic Progression in Psoriatic Arthritis: A Report from the GRAPPA 2011 Annual Meeting.
- GRAPPA Responder Index Project (GRACE): A Report from the GRAPPA 2011 Annual Meeting.
- On Defining Musculoskeletal Inflammation: A Report from the GRAPPA 2011 Annual Meeting.
- A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid Arthritis with an inadequate response to methotrexate.
- Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomised, placebo-controlled trial with...
- Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid Arthritis: a re...
- Development of responder definitions for Fibromyalgia clinical trials.
- Minimally Important Difference of Health Assessment Questionnaire in Psoriatic Arthritis: Relating Thresholds of Improvement in Functional Ability to Patient-rated Imp...
- Interpreting clinical trial results for moderate-to-severe rheumatoid Arthritis: Practical applications for rheumatology healthcare providers.
- The potential roles for novel biomarkers in rheumatoid Arthritis assessment.
- Pain Mechanisms in OsteoArthritis: Understanding the Role of Central Pain and Current Approaches to Its Treatment.
- Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Ra...
- Estimation of minimum clinically important difference for Pain in fibromyalgia.
- Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data (February).
- Psoriatic Arthritis treatment update.
- AJC editor's consensus: rheumatoid Arthritis and atherosclerotic cardiovascular disease.
- Managing comorbid disease in patients with psoriatic Arthritis.
- Psoriatic Arthritis: pharmacotherapy update.
- Development of screening tools to identify psoriatic Arthritis.
- Pain response profile of patients with fibromyalgia treated with duloxetine.
- Long-term safety, tolerability, and efficacy of duloxetine in the treatment of Fibromyalgia.
- Psoriatic Arthritis - update on pathophysiology, assessment, and management.
- Further strategies for treating Fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors.
- Fibromyalgia: key clinical domains, comorbidities, assessment and treatment.
- Treatment recommendations for psoriatic Arthritis.
- Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory Arthritis: a phase 1 dose-escalation s...
- Investigation of the cause of death in a gene-therapy trial.
- Psoriatic Arthritis assessment and treatment update.
- Pharmacotherapy of Fibromyalgia.
- Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid Arthritis clinical trials).
- Fibromyalgia. Preface.
- Adalimumab for long-term treatment of psoriatic Arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
- Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic Arthritis: Twenty-four-week efficac...
- Alefacept with methotrexate for treatment of psoriatic Arthritis: open-label extension of a randomized, double-blind, placebo-controlled study.
- Assessing the impact of psoriatic Arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions.
- Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?
- Nursing considerations for infusion therapy in rheumatoid Arthritis versus malignancy.
- Insights into the pathology and treatment of spondyloArthritis: from the bench to the clinic.
- SpondyloArthritis update: new insights regarding classifcation, pathophysiology, and management.
- Efalizumab for the treatment of psoriatic Arthritis.
- Adalimumab for long-term treatment of psoriatic Arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic Arthritis trial.
- Quality-of-life issues in psoriasis and psoriatic Arthritis: outcome measures and therapies from a dermatological perspective.
- Epidemiology of psoriatic Arthritis in the population of the United States.
- Psoriatic Arthritis therapy advances.
- Effects of prasterone on Disease activity and symptoms in women with active systemic lupus erythematosus.
- Etanercept treatment of psoriatic Arthritis: safety, efficacy, and effect on disease progression.
- Recent advances in the management of psoriatic Arthritis.
- Assessment of patients with psoriatic Arthritis: a review of currently available measures.
- Current treatment of psoriatic Arthritis.
- Disease-modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment.
- Etanercept in the treatment of adult patients with Still's Disease.
- Etanercept: a new era in the treatment of psoriatic Arthritis.
- Ms. A.M. Taylor, et al reply.
Schools
Stanford University School Of Medicine
University of Washington
Procedures Preformed
- Joint Drainage
- Steroid Injection
- Viscosupplementation With Hyaluronate
Conditions Treated
- Ankylosing Spondylitis
- Arthritis
- Behçet's Disease
- Bursitis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- America's Top Doctors
- Top MD
- Super Doctor
Education
-
University of Washington -
Stanford University School of Medicine
Hospital
-
Swedish Medical Center-Cherry Hill Campus
Drug Facts
| NPI NUMBER | 1336218171 | |
| NPPES Provider LastName | MEASE | |
| NPPES Provider FirstName | PHILIP | |
| NPPES Provider ZIPCode | 981043556 | |
| NPPES Provider State | WA | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 735.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 39.0 | |
| Percent Opioid Claims | 5.31 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1336218171 |
| Last Name Of The Provider | MEASE |
| First Name Of The Provider | PHILIP |
| View All |
Similar Doctors
|
|
Dr. Peter Mohai, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pamela B. Sheets, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grant C. Hughes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bernard S. Ng, MD |
|
|
Dr. John F. Dickson, MD |